Physician profile
Jeffery Lambert
NPI 1841280617
$4,652.68
in general payments reported to CMS, 2019-2025
34 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.90 · 2020: $35.40 · 2021: $377 · 2022: $808 · 2023: $913 · 2024: $1,285 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $948.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $587.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $503.01 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $293.04 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.60 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $241.76 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $194.38 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $187.14 | 2021-2025 | |
| Abbvie INC. | $149.02 | 2021-2024 | |
| Amgen INC. | $146.75 | 2023-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $108.76 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $97.08 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.72 | 2021-2025 | Jardiance |
| Bausch Health US, LLC | $85.26 | 2023-2024 | Aplenzin |
| Dexcom, INC. | $83.59 | 2023 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $80.83 | 2022 | |
| Merck Sharp & Dohme LLC | $74.15 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $64.35 | 2023-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $57.35 | 2022-2023 | Quviviq |
| Inspire Medical Systems, INC. | $45.73 | 2024 | Inspire |
| Harmony Biosciences LLC | $35.69 | 2024 | |
| Hologic Sales and Service, LLC | $35.48 | 2025 | Thinprep 2000 Processor |
| Allergan, INC. | $35.40 | 2020 | |
| Sunovion Pharmaceuticals INC. | $33.97 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.17 | 2019-2022 | |
| Corcept Therapeutics | $26.54 | 2025 | Korlym |
| Dynavax Technologies Corporation | $23.07 | 2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $19.12 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $17.85 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $17.84 | 2025 | Nuzyra |
| Eisai INC. | $15.51 | 2021 | |
| Currax Pharmaceuticals LLC | $14.27 | 2023 | Contrave, Onzetra Xsail |
| Ibsa Pharma INC. | $13.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.